SLP Stock Forecast 2025-2026
Distance to SLP Price Targets
SLP Price Momentum
10 Quality Stocks Worth Considering Now
Researching Simulations Plus (SLP) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SLP and similar high-potential opportunities.
Latest SLP Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, SLP has a bullish consensus with a median price target of $41.00 (ranging from $30.00 to $65.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $35.88, the median forecast implies a 14.3% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Francois Brisebois at Oppenheimer, projecting a 81.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLP Analyst Ratings
SLP Price Target Range
Latest SLP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $40.00 |
| Jan 24, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $37.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $35.00 |
| Nov 15, 2024 | Stephens & Co. | Jeff Garro | Overweight | Initiates | $39.00 |
| Nov 6, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Oct 24, 2024 | BTIG | David Larsen | Buy | Maintains | $50.00 |
| Oct 24, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Sep 12, 2024 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
| Jul 29, 2024 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $47.00 |
| Jul 16, 2024 | JMP Securities | Constantine Davides | Market Perform | Initiates | $0.00 |
| Jul 3, 2024 | Craig-Hallum | Matt Hewitt | Buy | Reiterates | $56.00 |
| Jun 28, 2024 | William Blair | Max Smock | Outperform | Initiates | $0.00 |
| Jun 13, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $56.00 |
| Jun 13, 2024 | Oppenheimer | Francois Brisebois | Outperform | Maintains | $65.00 |
| Jan 4, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $51.00 |
| Jul 7, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $67.00 |
| Jun 21, 2023 | Oppenheimer | Outperform | Maintains | $0.00 | |
| May 9, 2023 | BTIG | David Larsen | Buy | Initiates | $55.00 |
| Apr 6, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $65.00 |
| Aug 29, 2022 | Raymond James | Dane Leone | Outperform | Maintains | $70.00 |
Simulations Plus Inc. (SLP) Competitors
The following stocks are similar to Simulations Plus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Simulations Plus Inc. (SLP) Financial Data
Simulations Plus Inc. has a market capitalization of $709.11M with a P/E ratio of 97.9x. The company generates $78.56M in trailing twelve-month revenue with a 9.2% profit margin.
Revenue growth is +22.5% quarter-over-quarter, while maintaining an operating margin of +12.1% and return on equity of +4.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Simulations Plus Inc. (SLP) Business Model
About Simulations Plus Inc.
Provides software solutions for drug development.
Simulations Plus Inc. generates revenue by offering a suite of software tools designed for the pharmaceutical industry. These tools assist in drug development processes, enabling clients to optimize research and regulatory submissions, which ultimately leads to reduced costs and time for bringing new drugs to market.
The company serves a diverse range of clients within the life sciences sector, including biotechnology firms, pharmaceutical companies, and regulatory agencies. Its innovative software solutions are vital for accurate modeling of pharmaceutical compounds, enhancing the efficiency of research and contributing to advancements in healthcare globally.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
243
CEO
Country
United States
IPO Year
1997
Website
www.simulations-plus.comSimulations Plus Inc. (SLP) Latest News & Analysis
Latest News
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
3 days agoSimulations Plus, Inc. supports the FDA's roadmap to reduce animal testing using new approach methodologies (NAMs), enhancing its role in biopharma solutions.
Simulations Plus' support for the FDA's roadmap to reduce animal testing highlights its alignment with regulatory trends, potentially enhancing its market position and attracting investors focused on ethical innovation.
Simulations Plus, Inc. provides AI software for drug discovery, enhancing R&D efficiency. Favorable FDA regulations for AI and non-animal testing may increase its market potential despite high valuation.
Simulations Plus, Inc. stands to benefit from increased demand for AI tools in biotech, driven by FDA support for innovation, enhancing growth prospects despite high valuation concerns.
The FDA is shifting its evaluation of monoclonal antibody therapies and other drugs, moving away from traditional animal testing methods.
The FDA's shift in drug evaluation could expedite approvals and reduce costs for biotech firms, potentially increasing investment opportunities in innovative therapies.
Simulations Plus (NASDAQ: SLP) will hold its Q2 2025 earnings conference call on April 3, 2025, at 5 PM ET, featuring key company executives and analysts from various firms.
The Q2 2025 earnings call for Simulations Plus could reveal key financial metrics and strategic insights, impacting stock performance and investor sentiment.
Simulations Plus, Inc. reported a 23% increase in total revenue, reaching $22.4 million for Q2 fiscal 2025, compared to the same quarter in 2024.
Simulations Plus reported a 23% revenue increase, signaling growth and strong demand in the biopharma sector, which could enhance investor confidence and drive stock prices.
Simulations Plus (SLP) reported Q4 earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.25, and up from $0.20 per share year-over-year.
Simulations Plus (SLP) exceeded earnings expectations, indicating strong financial performance and growth, which may boost investor confidence and positively impact stock price.
Frequently Asked Questions About SLP Stock
What is Simulations Plus Inc.'s (SLP) stock forecast for 2025?
Based on our analysis of 10 Wall Street analysts, Simulations Plus Inc. (SLP) has a median price target of $41.00. The highest price target is $65.00 and the lowest is $30.00.
Is SLP stock a good investment in 2025?
According to current analyst ratings, SLP has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLP stock?
Wall Street analysts predict SLP stock could reach $41.00 in the next 12 months. This represents a 14.3% increase from the current price of $35.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Simulations Plus Inc.'s business model?
Simulations Plus Inc. generates revenue by offering a suite of software tools designed for the pharmaceutical industry. These tools assist in drug development processes, enabling clients to optimize research and regulatory submissions, which ultimately leads to reduced costs and time for bringing new drugs to market.
What is the highest forecasted price for SLP Simulations Plus Inc.?
The highest price target for SLP is $65.00 from Francois Brisebois at Oppenheimer, which represents a 81.2% increase from the current price of $35.88.
What is the lowest forecasted price for SLP Simulations Plus Inc.?
The lowest price target for SLP is $30.00 from at , which represents a -16.4% decrease from the current price of $35.88.
What is the overall SLP consensus from analysts for Simulations Plus Inc.?
The overall analyst consensus for SLP is bullish. Out of 10 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $41.00.
How accurate are SLP stock price projections?
Stock price projections, including those for Simulations Plus Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.